Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Abstract

Limited response to immune checkpoint inhibitors has been reported in patients with castration-resistant prostate cancer. Here the authors show that intermittent, but not continuous, treatment with an anti-PI3Kα/β/δ-inhibitor promotes anti-tumor immunity and response to PD-1 blockade in a preclinical Pten-null model of prostate cancer.